Erdheim–Chester disease

Erdheim–Chester disease
Other names: Erdheim–Chester syndrome or Polyostotic sclerosing histiocytosis
Chester-Erdheim disease

Erdheim–Chester disease (ECD) is an extremely rare disease characterized by the abnormal multiplication of a specific type of white blood cells called histiocytes, or tissue macrophages (technically, this disease is termed a non-Langerhans-cell histiocytosis). It was declared a histiocytic neoplasm by the World Health Organization in 2016.^[1] Onset typically is in middle age. The disease involves an infiltration of lipid-laden macrophages, multinucleated giant cells, an inflammatory infiltrate of lymphocytes and histiocytes in the bone marrow, and a generalized sclerosis of the long bones.^[2]

Signs and symptoms

Long bone involvement is almost universal in ECD patients and is bilateral and symmetrical in nature. More than 50% of cases have some sort of extraskeletal involvement. This can include kidney, skin, brain and lung involvement, and less frequently retroorbital tissue, pituitary gland and heart involvement is observed.^[3]

Bone pain is the most frequent of all symptoms associated with ECD and mainly affects the lower limbs, knees and ankles. The pain is often described as mild but permanent, and in tissues near an articulation, or joint in nature. Exophthalmos occurs in some patients and is usually bilateral, symmetric and painless, and in most cases it occurs several years before the final diagnosis. Recurrent pericardial effusion can be a manifestation,^[4] as can morphological changes in adrenal size and infiltration.^[5]

A review of 59 case studies by Veyssier-Belot et al. in 1996 reported the following symptoms in order of frequency of occurrence:^[6]

• Bone pain
• Retroperitoneal fibrosis
• Diabetes insipidus
• Exophthalmos
• Xanthomas
• Neurological signs (including ataxia)
• Dyspnea caused by interlobular septal and pleural thickening.
• Kidney failure
• Hypopituitarism
• Liver failure

Cause

The cause of this condition is yet not known, however it is suspected that it is either a reactive or neoplastic disorder (many affected individuals have mutations in the BRAF proto-oncogene)^[7]

Diagnosis

Radiologic osteosclerosis and histology are the main diagnostic features. Diagnosis can often be difficult because of the rareness of ECD as well as the need to differentiate it from LCH. A diagnosis from neurological imaging may not be definitive. The presence of symmetrical cerebellar and pontine signal changes on T2-weighted images seem to be typical of ECD, however, multiple sclerosis and metabolic diseases must also be considered in the differential diagnosis.^[8] ECD is not a common cause of exophthalmos but can be diagnosed by biopsy. However, like all biopsies, this may be inconclusive.^[9] Video-assisted thoracoscopic surgery may be used for diagnostic confirmation and also for therapeutic relief of recurrent pericardial fluid drainage.^[10]

Histology

Histologically, ECD differs from Langerhans cell histiocytosis (LCH) in a number of ways. Unlike LCH, ECD does not stain positive for S-100 proteins or Group 1 CD1a glycoproteins, and electron microscopy of cell cytoplasm does not disclose Birbeck granules.^[6] Tissue samples show xanthomatous or xanthogranulomatous infiltration by lipid-laden or foamy histiocytes, and are usually surrounded by fibrosis. Bone biopsy is said to offer the greatest likelihood of reaching a diagnosis. In some, there is histiocyte proliferation, and on staining, the section is CD68+ and CD1a-.

a)Xanthogranulomatous infiltrate b) stain for BRAFV600E c) and p16Ink4a

Treatment

Current treatment options for this condition include:

• Surgical debulking
• High-dose corticosteroid therapy
• Ciclosporin
• Interferon-α^[9]
• Chemotherapy
• Vemurafenib. It would appear that approximately half these patients harbor point mutations of the BRAF gene at codon 600 substituting the amino acid glutamine for valine. Vemurafenib, an oral FDA approved targeted agent to the BRAF protein for melanoma, shows dramatic activity in patients Erdheim–Chester disease whose tumor contains the same mutation.^[11] In 2017 the US FDA approved vemurafenib for this indication.^[12]
• Radiation therapy

All current treatments have had varying degrees of success.

The vinca alkaloids and anthracyclines have been used most commonly in ECD treatment.^[13]

Prognosis

Erdheim–Chester disease is associated with high mortality rates.^[10][14] In 2005, the survival rate was below 50% at three years from diagnosis.^[15] More recent reports of patients treated with Interferon therapy describe an overall 5-year survival of 68%.^[16] Long-term survival is currently even more promising, although this impression is not reflected in the recent literature.^[17]

Epidemiology

Approximately 500 cases have been reported in the literature to date.^[18] ECD affects predominantly adults, with a mean age of 53 years.^[6]

History

The first case of ECD was reported by the American pathologist William Chester in 1930, during his visit to the Austrian pathologist Jakob Erdheim in Vienna.^[19]

Society and culture

References

Further reading

External links

• 01067 at CHORUS